Recent Advances in the Treatment of Alopecia Areata - Episode 12
Assessing Risk and Safety of JAK Inhibitors
Panelists discuss the efficacy and safety data for ritlecitinib and deuruxolitinib in treating alopecia areata, highlighting that ritlecitinib achieved SALT scores of ≤20 in 23% of patients at week 24 compared to 1.6% in the placebo group, while deuruxolitinib showed SALT scores of ≤20 in 42.5% (8mg BID ) and 56.8% (12mg BID) of patients, with treatment-emergent adverse events primarily being mild to moderate, including upper respiratory tract infections and headaches for ritlecitinib, and headache and acne for deuruxolitinib.
Video content above is prompted by the following:
a. Ritlecitinib (n=261, King 2023)
i.SALT≤20 at week 24 was achieved by 23% (50mg QD) and 1.6% (placebo) of patients; SALT≤10 at week 24 was achieved by 13.4% (50 mg QD) and 1.5% (placebo) of patients.
ii. TEAEs were reported by 75% of patients on 50 mg QD ritlecitinib and 71% on placebo group. Discontinuations were reported by 2% of patients in both groups. Most common AEs (occurred in ≥10% of patients) were upper respiratory tract infection, nasopharyngitis, and headache. b. Deuruxolitinib (n=706, King 2024):
iii. SALT ≤20 after 24 weeks was achieved by 42.5% (8 mg BID), 56.8% (12mg BID), 1.8% (placebo) of patients with partial hair loss and by 20.1% (8 mg BID), 29.5% (12 mg BID), 0% (placebo) of patients with complete or near-complete hair loss.
iv. TEAEs related to study drug were reported by 31.3% (8 mg BID), 34.9% (12 mg BID), 22.1% (placebo). Most TEAEs were mild to moderate. Headache, acne, and increased blood creatinine phosphokinase were the most common TEAEs (occurred in ≥5% patients). No heart-related AEs were reported.
